Molecular biomarkers in urothelial bladder cancer
- 28 March 2008
- journal article
- review article
- Published by Wiley in Cancer Science
- Vol. 99 (4), 646-652
- https://doi.org/10.1111/j.1349-7006.2008.00735.x
Abstract
Bladder cancers are a mixture of heterogeneous cell populations, and numerous factors are likely to be involved in dictating their recurrence, progression, and the patient's survival. For any candidate prognostic marker to have considerable clinical relevance, it must add some predictive capacity beyond that offered by the conventional clinical and pathological parameters. None of the biomarkers reported to date have shown sufficient sensitivity and specificity for detecting the whole spectrum of bladder cancer diseases in routine clinical practice. The limitations of established prognostic markers requires us to identify better molecular parameters that could be of interest in predicting the prognosis of bladder cancer patients, in particular, the high-risk patient groups that are at risk of progression and recurrence. Recent progress in epigenetic modification and gene silencing opened a new avenue for the identification of epigenetic markers, which appears to be more useful for cancer diagnosis and prognosis. Although epigenetic markers also have limitations, the combined epigenetic marker approach may increase sensitivity and reliability. The epigenetic silencing of tumor-suppressor genes is interesting from a clinical standpoint because of the possibility of reversing epigenetic changes and restoring gene function in a cell. In addition, microarray technology provides us with additional tools for the analysis of global gene-expression analysis of tumor samples. Future microarray analyses are likely to reveal particular gene-expression signatures that predict the likelihood of bladder cancer progression and recurrence, as well as a patient's survival and responsiveness to different anticancer therapies, with great specificity and sensitivity.Keywords
This publication has 74 references indexed in Scilit:
- Promoter Hypermethylation Identifies Progression Risk in Bladder CancerClinical Cancer Research, 2007
- CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancerNature Genetics, 2006
- CYP2E1 and NQO1 genotypes, smoking and bladder cancerPharmacogenetics, 2003
- Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical OutcomeJournal of Clinical Oncology, 2003
- OVER EXPRESSION OF CD44V8-10 IN URINARY EXFOLIATED CELLS AS AN INDEPENDENT PROGNOSTIC PREDICTOR IN PATIENTS WITH UROTHELIAL CANCERJournal of Urology, 2002
- POLYMORPHISMS OF N-ACETYLTRANSFERASE 2, GLUTATHIONE S-TRANSFERASE MU AND THETA GENES AS RISK FACTORS OF BLADDER CANCER IN RELATION TO ASTHMA AND TUBERCULOSISJournal of Urology, 2000
- Prognostic values of matrix metalloproteinase‐2 and tissue inhibitor of metalloproteinase‐2 expression in bladder cancerCancer, 1998
- Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunitiesThe Journal of Pathology, 1995
- Detection of the c‐myc Gene Product in Urinary Bladder CancerJapanese Journal of Cancer Research, 1990